Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

Dougados, M. et al. (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases, 73(1), pp. 62-68. (doi:10.1136/annrheumdis-2013-204223)

89175.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.



Background: Patients with rheumatoid arthritis (RA) are at increased risk of developing comorbid conditions.

Objectives: To evaluate the prevalence of comorbidities and compare their management in RA patients from different countries worldwide.

Methods Study design: international, cross-sectional. Patients: consecutive RA patients. Data collected: demographics, disease characteristics (activity, severity, treatment), comorbidities (cardiovascular, infections, cancer, gastrointestinal, pulmonary, osteoporosis and psychiatric disorders).

Results: Of 4586 patients recruited in 17 participating countries, 3920 were analysed (age, 56±13 years; disease duration, 10±9 years (mean±SD); female gender, 82%; DAS28 (Disease Activity Score using 28 joints)–erythrocyte sedimentation rate, 3.7±1.6 (mean±SD); Health Assessment Questionnaire, 1.0±0.7 (mean±SD); past or current methotrexate use, 89%; past or current use of biological agents, 39%. The most frequently associated diseases (past or current) were: depression, 15%; asthma, 6.6%; cardiovascular events (myocardial infarction, stroke), 6%; solid malignancies (excluding basal cell carcinoma), 4.5%; chronic obstructive pulmonary disease, 3.5%. High intercountry variability was observed for both the prevalence of comorbidities and the proportion of subjects complying with recommendations for preventing and managing comorbidities. The systematic evaluation of comorbidities in this study detected abnormalities in vital signs, such as elevated blood pressure in 11.2%, and identified conditions that manifest as laboratory test abnormalities, such as hyperglycaemia in 3.3% and hyperlipidaemia in 8.3%.

Conclusions: Among RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain
Authors: Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M.H., Casado, G., Detert, J., El-zorkany, B., Emery, P., Hajjaj-Hassouni, N., Harigai, M., Luo, S.-F., Kurucz, R., Maciel, G., Mola, E.M., Montecucco, C.M., McInnes, I., Radner, H., Smolen, J. S., Song, Y.-W., Vonkeman, H.E., Winthrop, K., and Kay, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Annals of the Rheumatic Diseases
Publisher:B M J Group
ISSN (Online):1468-2060
Copyright Holders:Copyright © 2013 The Authors
First Published:First published in Annals of the Rheumatic Diseases 73(1):62-68
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record